Memantine was synthesised by Eli Lilly and Company in 1968 and was approved by FDA for treatment of moderate-to-severe Alzheimer’s disease. Off-label use of Memantine comprises reversing tolerance for caffeine, nicotine and opioids. it might also be taken for a treatment of generalised anxiety disorder.
Memantine is NMDA receptor antagonist that stimulates the processes of neurotransmission. It also increases the brain activity and other cognitive functions.
- Dementia (Alzheimer’s type, vascular, mixed dementia of all degrees of severity)
- Dysfunction of the central nervous system of mild to moderate severity (weakening of memory and ability to concentrate, loss of interest in activities, fatigue, limiting the ability to care for themselves)
- Cerebral and spinal spastic syndrome (due to traumatic brain injury, multiple sclerosis, stroke)
- Parkinson’s disease, parkinsonism
- Impaired memory capacity for concentration and learning ability.
Country of origin: Russia